Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

25 Oct 2016 17:43

RNS Number : 4431N
GW Pharmaceuticals PLC
25 October 2016
Β 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with themΒ 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Mr Julian Gangolli

2.

Reason for the notification

a.

Position/status

Director/President, US

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

Β 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Β 

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

Β 

c.

Price(s) and volume(s)

Β 

Price(s)

Β 0.1p

Volume(s)

10,608

Β 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

Β·Aggregated volume

Β·Price

Β 

Β 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Β London

Β 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

Β Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: US36197T1034

b.

Nature of the transaction

Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)

c.

Price(s) and volume(s)

Β 

Price(s)

Β -

Volume(s)

301

Β 

ADS's issued upon conversion of 3,612 Ordinary shares

d.

Aggregated information

Β·Aggregated volume

Β·Price

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Β 

Β 

American Depositary Shares

ISIN: 36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

c.

Price(s) and volume(s)

Β 

Price(s)

Β $120.75

Volume(s)

301

Β 

ADS's sold

d.

Aggregated information

Β·Aggregated volume

Β·Price

Β 

Β 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary Share and Restricted American Depositary Shares

Ordinary Shares: ISIN: GB0030544687

Restricted American Depositary shares: ISIN: US36197T1372

b.

Nature of the transaction

Conversion of Ordinary Shares into Restricted American Depositary sharesΒ (12 to 1 Conversion ratio)

c.

Price(s) and volume(s)

Β 

Price(s)

Β -

Volume(s)

583

Restricted ADSs issued upon conversion of 6,996 Ordinary Shares

d.

Aggregated information

Β·Aggregated volume

Β·Price

Β 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York

Β 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Mr Christopher Tovey

2.

Reason for the notification

a.

Position/status

Director/Chief Operations Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

Β 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

c.

Price(s) and volume(s)

Β 

Price(s)

Β 0.1p

Volume(s)

266,557

Β 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

Β·Aggregated volume

Β·Price

Β 

Β 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Β London

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

Β Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: US36197T1034

b.

Nature of the transaction

Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)

c.

Price(s) and volume(s)

Β 

Price(s)

Β -

Volume(s)

22,213

ADS's issued upon conversion of 266,556 Ordinary shares

d.

Aggregated information

Β·Aggregated volume

Β·Price

Β 

Β 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

American Depositary Shares

ISIN: US36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

c.

Price(s) and volume(s)

Β 

Price(s)

Β $120.36

Volume(s)

22,213

Β 

ADS's sold

d.

Aggregated information

Β·Aggregated volume

Β·Price

Β 

Β 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New YorkΒ 

Β 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Geoffrey Guy

2.

Reason for the notification

a.

Position/status

Director/Chairman of the Board

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

Β 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary Shares

c.

Price(s) and volume(s)

Β 

Price(s)

Β Β£8.43p

Volume(s)

206,100

Β 

Ordinary shares sold

d.

Aggregated information

Β·Aggregated volume

Β·Price

Β 

Β 

n/a

e.

Date of the transaction

21 October 2016

f.

Place of the transaction

Β AIM, London

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

Β Ordinary Shares: ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary shares

c.

Price(s) and volume(s)

Β 

Price(s)

Β Β£8.24

Volume(s)

68,900

Β 

Ordinary shares sold

d.

Aggregated information

Β·Aggregated volume

Β·Price

Β 

Β 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

AIM, London

Β 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

0.1 Pence Ordinary Shares

ISIN:GB0030544687

b.

Nature of the transaction

Sale of Ordinary shares

c.

Price(s) and volume(s)

Β 

Price(s)

Β Β£8.09

Volume(s)

125,000

Β 

Ordinary Shares sold

d.

Aggregated information

Β·Aggregated volume

Β·Price

Β 

Β 

n/a

e.

Date of the transaction

25 October 2016

f.

Place of the transaction

AIM, London

Β 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Stephen Wright

2.

Reason for the notification

a.

Position/status

Director/Chief Medical Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

Β 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary Shares by the wife of Dr Stephen Wright

c.

Price(s) and volume(s)

Β 

Price(s)

Β Β£8.10p

Volume(s)

1,556

Β 

Ordinary shares sold

d.

Aggregated information

Β·Aggregated volume

Β·Price

Β 

Β 

n/a

e.

Date of the transaction

25 October 2016

f.

Place of the transaction

Β AIM, London

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHLLFSRIILEFIR
Date   Source Headline
18th Feb 201410:20 amRNSBlocklisting Interim Review
12th Feb 20141:47 pmRNSAdditional Listing
10th Feb 20145:00 pmRNSPresenting at Leerink Global Healthcare Conference
5th Feb 20147:00 amRNSQ1 2014 Financial Results and Operational Progress
31st Jan 20143:17 pmRNSHolding(s) in Company
29th Jan 20147:00 amRNSNotice of Results
17th Jan 20145:11 pmRNSHolding(s) in Company
16th Jan 201411:13 amRNSAdditional Listing
15th Jan 20144:34 pmRNSHolding(s) in Company
15th Jan 20144:33 pmRNSHolding(s) in Company
14th Jan 20144:23 pmRNSClosing of U.S. Follow-on Offering of Nasdaq ADSs
14th Jan 20147:00 amRNSAgreement with Ipsen for Sativex in Latin America
13th Jan 20145:00 pmRNSHolding(s) in Company
13th Jan 20145:00 pmRNSHolding(s) in Company
9th Jan 20147:00 amRNSRaises $87.9m on NASDAQ in U.S. Follow-On Offering
6th Jan 201412:18 pmRNSResults of General Meeting
6th Jan 201412:13 pmRNSFiles Amendment to Registration Statement
20th Dec 20132:05 pmRNSNotice of General Meeting and Follow-On Offering
11th Dec 20137:00 amRNSU.S. Patent Allowance for Cannabinoids in Glioma
6th Dec 20135:52 pmRNSPublication of UK Annual Report and Accounts
2nd Dec 20137:00 amRNSPresenting at Piper Jaffray Health Care Conference
29th Nov 20132:00 pmRNSBlocklisting Application
27th Nov 20137:00 amRNSSativex Regulatory Approval in Switzerland
26th Nov 20135:51 pmRNSDirector/PDMR Shareholding
26th Nov 20137:00 amRNSFiling of U.S. Annual Report on Form 20-F
19th Nov 20137:00 amRNSFinal Results
18th Nov 20136:00 pmRNSGW Presenting at Jefferies Healthcare Conference
15th Nov 20137:00 amRNSUpdate on Epidiolex in Childhood Epilepsy
12th Nov 20137:01 amRNSNotice of Results
11th Nov 20137:00 amRNSPhase 1b/2a trial for Glioblastoma Multiforme
21st Oct 20137:00 amRNSSuccessful Closing of Mutual Recognition Procedure
2nd Oct 20138:00 amRNSNew Sativex Data at ECTRIMS
24th Sep 20132:01 pmRNSGrant of Options
23rd Sep 201311:41 amRNSAgreement on Sativex Pricing in Germany
20th Sep 20137:00 amRNSPresenting at Aegis Capital Healthcare Conference
18th Sep 20137:00 amRNSGW Commences Trial of GWP42006 for Epilepsy
19th Aug 20137:00 amRNSBlocklisting Interim Review
14th Aug 20137:00 amRNSInvestigational New Drug Application for Sativex
8th Aug 20137:00 amRNSPresenting at the Canaccord Genuity Conference
5th Aug 20137:00 amRNS2013 Third Quarter Financial Results
5th Aug 20137:00 amRNSSativex MS Spasticity Cognition Study Results
22nd Jul 20137:00 amRNSFiles new application to expand Sativex to France
15th Jul 20137:00 amRNSNotice of Results
8th Jul 20137:00 amRNSProduct Launch
4th Jul 20138:31 amRNSHolding(s) in Company
10th Jun 201312:53 pmRNSDirector/PDMR Shareholding
3rd Jun 20137:00 amRNSSecond Quarter Financial Results
30th May 20135:30 pmRNSExercise of Over-Allotment Option
14th May 20131:00 pmRNSNotice of Results
10th May 20134:28 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.